Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ieva Stirblyte"'
Autor:
Daisuke Suzuki, Charlotte Flahou, Norihide Yoshikawa, Ieva Stirblyte, Yoshikazu Hayashi, Akira Sawaguchi, Marina Akasaka, Sou Nakamura, Natsumi Higashi, Huaigeng Xu, Takuya Matsumoto, Kosuke Fujio, Markus G. Manz, Akitsu Hotta, Hitoshi Takizawa, Koji Eto, Naoshi Sugimoto
Publikováno v:
Stem Cell Reports, Vol 14, Iss 1, Pp 49-59 (2020)
Summary: The ex vivo production of platelets depleted of human leukocyte antigen class I (HLA-I) could serve as a universal measure to overcome platelet transfusion refractoriness caused by HLA-I incompatibility. Here, we developed human induced plur
Externí odkaz:
https://doaj.org/article/9f437e1b02f6488582832358c907a1bf
Autor:
Natsumi Higashi, Yoshikazu Hayashi, Akitsu Hotta, Kosuke Fujio, Hitoshi Takizawa, Koji Eto, Markus G. Manz, Marina Akasaka, Charlotte Flahou, Huaigeng Xu, Takuya Matsumoto, Sou Nakamura, Daisuke Suzuki, Norihide Yoshikawa, Naoshi Sugimoto, Ieva Stirblyte, Akira Sawaguchi
Publikováno v:
Stem Cell Reports, Vol 14, Iss 1, Pp 49-59 (2020)
Stem Cell Reports
Stem Cell Reports
Summary The ex vivo production of platelets depleted of human leukocyte antigen class I (HLA-I) could serve as a universal measure to overcome platelet transfusion refractoriness caused by HLA-I incompatibility. Here, we developed human induced pluri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72d31e2a5eb0ae00a52465f0d6628715
https://doi.org/10.5167/uzh-180152
https://doi.org/10.5167/uzh-180152
Autor:
Ruta Navakauskiene, Giedre Valiuliene, Ieva Stirblyte, Mindaugas Valius, Dovile Cicenaite, Algirdas Kaupinis
Publikováno v:
Journal of cellular and molecular medicine, Oxford : Wiley-Blackwell Publishing Ltd., 2015, vol. 19, no. 7, p. 1742-1755
Journal of Cellular and Molecular Medicine
Journal of Cellular and Molecular Medicine
Epigenetic changes play a significant role in leukaemia pathogenesis, therefore histone deacetylases (HDACis) are widely accepted as an attractive strategy for acute promyelocytic leukaemia (APL) treatment. Belinostat (Bel, PXD101), a hydroxamate-typ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96f0e5cd25dc620cf3e762f89149878d
https://repository.vu.lt/VU:ELABAPDB13940727&prefLang=en_US
https://repository.vu.lt/VU:ELABAPDB13940727&prefLang=en_US
Publikováno v:
Anti-cancer drugs. 25(8)
Therapeutic strategies targeting histone deacetylase (HDAC) inhibition have become promising in many human malignancies. Belinostat (PXD101) is a hydroxamate-type HDAC inhibitor tested in phase I and II clinical trials in solid tumors and hematologic
Publikováno v:
Leukemia research. 38(7)
The involvement of histone lysine methyltransferases (HMT) in carcinogenesis is not well understood. Here, we describe a dose-dependent growth and survival inhibitory effects of BIX-01294, a specific inhibitor of euchromatic HMT2, in promyelocytic le